X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs STRIDES SHASUN LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA STRIDES SHASUN LTD CIPLA/
STRIDES SHASUN LTD
 
P/E (TTM) x 44.1 14.0 315.5% View Chart
P/BV x 3.6 1.9 192.3% View Chart
Dividend Yield % 0.4 0.6 64.1%  

Financials

 CIPLA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    CIPLA
Mar-17
STRIDES SHASUN LTD
Mar-16
CIPLA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs6221,413 44.0%   
Low Rs458848 54.0%   
Sales per share (Unadj.) Rs181.9353.3 51.5%  
Earnings per share (Unadj.) Rs12.923.4 55.0%  
Cash flow per share (Unadj.) Rs29.341.0 71.5%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.40.4 83.7%  
Book value per share (Unadj.) Rs155.7320.4 48.6%  
Shares outstanding (eoy) m804.5189.35 900.4%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.03.2 92.8%   
Avg P/E ratio x42.048.3 86.8%  
P/CF ratio (eoy) x18.427.6 66.8%  
Price / Book Value ratio x3.53.5 98.4%  
Dividend payout %15.521.4 72.7%   
Avg Mkt Cap Rs m434,516100,988 430.3%   
No. of employees `00023.04.7 491.3%   
Total wages/salary Rs m26,3384,988 528.0%   
Avg. sales/employee Rs Th6,349.16,730.0 94.3%   
Avg. wages/employee Rs Th1,143.01,063.6 107.5%   
Avg. net profit/employee Rs Th449.3445.5 100.9%   
INCOME DATA
Net Sales Rs m146,30231,564 463.5%  
Other income Rs m2,2871,212 188.7%   
Total revenues Rs m148,58932,776 453.4%   
Gross profit Rs m24,7585,213 474.9%  
Depreciation Rs m13,2291,573 841.1%   
Interest Rs m1,5941,803 88.4%   
Profit before tax Rs m12,2223,049 400.8%   
Minority Interest Rs m0127 0.0%   
Prior Period Items Rs m-70-27 259.9%   
Extraordinary Inc (Exp) Rs m0-371 0.0%   
Tax Rs m1,798689 261.1%   
Profit after tax Rs m10,3542,089 495.6%  
Gross profit margin %16.916.5 102.5%  
Effective tax rate %14.722.6 65.1%   
Net profit margin %7.16.6 106.9%  
BALANCE SHEET DATA
Current assets Rs m87,37035,949 243.0%   
Current liabilities Rs m33,08119,402 170.5%   
Net working cap to sales %37.152.4 70.8%  
Current ratio x2.61.9 142.5%  
Inventory Days Days8771 122.6%  
Debtors Days Days62127 49.1%  
Net fixed assets Rs m111,56734,478 323.6%   
Share capital Rs m1,609894 180.1%   
"Free" reserves Rs m123,64522,601 547.1%   
Net worth Rs m125,25428,632 437.5%   
Long term debt Rs m36,45427,455 132.8%   
Total assets Rs m209,53276,591 273.6%  
Interest coverage x8.72.7 322.1%   
Debt to equity ratio x0.31.0 30.4%  
Sales to assets ratio x0.70.4 169.4%   
Return on assets %5.75.1 112.2%  
Return on equity %8.37.3 113.3%  
Return on capital %8.58.2 104.1%  
Exports to sales %34.248.1 71.1%   
Imports to sales %8.314.5 57.7%   
Exports (fob) Rs m50,05015,192 329.4%   
Imports (cif) Rs m12,2034,565 267.3%   
Fx inflow Rs m51,06616,612 307.4%   
Fx outflow Rs m17,6785,292 334.0%   
Net fx Rs m33,38811,320 295.0%   
CASH FLOW
From Operations Rs m23,824717 3,324.5%  
From Investments Rs m-13,127-22,284 58.9%  
From Financial Activity Rs m-13,23929,488 -44.9%  
Net Cashflow Rs m-2,4788,073 -30.7%  

Share Holding

Indian Promoters % 16.0 27.7 57.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 37.8 32.3%  
FIIs % 23.7 8.6 275.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 25.9 101.2%  
Shareholders   161,166 56,241 286.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 18, 2017 (Close)

TRACK CIPLA

CIPLA - TTK HEALTHCARE COMPARISON

COMPARE CIPLA WITH

MARKET STATS